Hello and welcome to the details of US FDA approves first test to identify opioid use addiction risk and now with the details
Nevin Al Sukari - Sana'a - The US FDA has approved the first test to assess if there is a risk of opioid use addiction in certain individuals. — Reuters pic
WASHINGTON, Dec 20 ― The US Food and Drug Administration (FDA) said yesterday it has approved the first test to assess if there is a risk of opioid use addiction in certain individuals.
The test, AvertD, is developed by privately held SOLVD Health. The FDA granted the approval to AutoGenomics, a unit that SOLVD acquired in 2019.
AvertD is intended to be used before the first use of oral opioid painkillers in those who are being considered for a 4 to 30 days prescription for the treatment of acute pain, such as in patients scheduled to undergo a planned surgical procedure.
Advertisement
It is a prescription-use only genetic laboratory test for patients 18 years and older for those who have not previously used oral opioid painkillers.
The test involves swabbing the cheek of a patient to collect a DNA sample that is then used to determine if there is a combination of genetic variants that may be associated with an elevated risk of developing opioid use disorder.
The addictive potential of the painkillers has fueled an opioid epidemic that has caused more than half a million overdose deaths in the United States over a period spanning more than two decades.
Advertisement
AvertD is not intended to be used in patients being treated for chronic pain, the FDA said.
An advisory panel to the health regulator in October last year had convened to discuss an earlier version of the test. ― Reuters
These were the details of the news US FDA approves first test to identify opioid use addiction risk for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
